SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated ...
Panel A shows the profile of autoantibodies binding to factor B, C3b, and C3 activation fragments in Patients 1 and 2. I bars denote the standard deviation of three independent tests. As shown in ...
Pegcetacoplan (Empaveli) reduced proteinuria and helped stabilize kidney function in patients with C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (MPGN). The C3 and C3b ...
Nanomedicine shows great promise in drug delivery due to its versatility in drug loading and ability to target the tissue of interest; however, its current applicability is significantly hindered by ...
Discrimination between self and non-self surfaces by the complement system of innate immunity has long been enigmatic. Finally, two papers provide structural insights into host protection against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results